Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Vodafone Q1 underlying earnings up 4.9pc, reiterates FY guidance

(Sharecast News) - Telecommunications giant Vodafone reiterated its FY26 guidance on Thursday as it said both revenue and underlying earnings had grown in Q1. Vodafone said group total revenue increased by 3.9% to €9.4bn in Q1, driven by strong service revenue growth, up 5.3% at €7.9bn.

German services revenues were down 3.2%, while UK service revenues grew 0.9%, African services revenues were 13.8% higher, Türkish services revenues shot up 29.6% and services revenues in Vodafone's Other Europe segment were broadly flat year-on-year, as good business growth across its footprint was offset by a decline in consumer revenues in Portugal and Romania.

Vodafone said adjusted underlying earnings increased by 4.9% on an organic basis to €2.7bn, as service revenue growth in most markets was partially offset by the impact of TV law changes in Germany and continued commercial investments. Adjusted underlying earnings margins of 29.3% were 0.2 percentage points higher year-on-year on an organic basis.

Operating profits decreased by 34.3% to €1.0bn, primarily due to higher "other income" in Q125 arising from the sale of Vodafone's stake in Indus Towers.

Looking ahead, Vodafone noted that following the completion of its UK merger with Three, its guidance now includes the impact of the transaction, with group adjusted underlying earnings of €11.3bn-€11.6bn and group adjusted free cash flow of €2.4bn-€2.6bn.

As of 0840 BST, Vodafone shares were down 0.61% at 82.65p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.